Severity
Low
FDA Drug recall · Reported July 15, 2015
Subpotent Drug: menthol and methyl salicylate below specification
BioComp Pharma, Inc. recalled Maximum Strength Analgesic Thera-Gesic Pain Relieving Creme Relief from: Joint and Muscle… - a low-severity action.
Maximum Strength Analgesic Thera-Gesic Pain Relieving Creme Relief from: Joint and Muscle… was recalled by BioComp Pharma, Inc. in July 15, 2015. Reason: Subpotent Drug: menthol and methyl salicylate below specification. Check the official notice for the remedy. Verify recall #D-1233-2015 with the FDA Drug before acting.
The recall
BioComp Pharma, Inc. issued this low-severity FDA Drug recall-Subpotent Drug: menthol and methyl salicylate below specification.
Sourced from official FDA Drug enforcement records. Verify recall #D-1233-2015 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1233-2015) was formally reported on July 15, 2015, with the manufacturer initiating the action on July 6, 2015. It is classified under Low severity (Class III), with a current status of Terminated. BioComp Pharma, Inc. is listed as the recalling firm, operating out of San Antonio, TX. Federal records list the affected scope as 40,000 sachets.
The documented reason for this recall is: Subpotent Drug: menthol and methyl salicylate below specification Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
40,000 sachets
Related Recalls
6
5 from same agency
Maximum Strength Analgesic Thera-Gesic Pain Relieving Creme Relief from: Joint and Muscle Soreness, Arthritis, Back Aches; 1/8 Oz Sachet, OTC, Manufactured for Mission Pharmacal Company 10999 IH 10 West, Suite 1000 San Antonio, TX 78230 by Mission Pharmacal Company 38505 IH 10 West Boerne, TX 78006. NDC 0178-0320-12
Subpotent Drug: menthol and methyl salicylate below specification
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1233-2015 |
| Date reported | July 15, 2015 |
| Date initiated | July 6, 2015 |
| Recalling firm | BioComp Pharma, Inc. |
| Firm location | San Antonio, TX |
| Affected scope | 40,000 sachets |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 15, 2015. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.